Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 1,462 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Soligenix Inc | SNGX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.014 | 3.72% | 0.39 | 06:14:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.376 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 8 | 1,462 | - | 0.3609 - 2.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 05:14:23 | 90 | $ 0.3758 | USD |
Soligenix Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.94M | 10.38M | - | 839k | -6.14M | -0.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Soligenix News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNGX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.3992 | 0.405 | 0.3609 | 0.3774854 | 251,525 | -0.0092 | -2.30% |
| 1 Month | 0.406 | 0.44 | 0.3609 | 0.3964045 | 243,671 | -0.016 | -3.94% |
| 3 Months | 0.71 | 0.9322 | 0.3609 | 0.4695923 | 2,814,282 | -0.32 | -45.07% |
| 6 Months | 0.4148 | 2.00 | 0.3609 | 0.7019319 | 2,871,180 | -0.0248 | -5.98% |
| 1 Year | 0.7651 | 2.00 | 0.3609 | 0.6973312 | 1,479,636 | -0.3751 | -49.03% |
| 3 Years | 15.60 | 20.10 | 0.3609 | 5.59 | 862,323 | -15.21 | -97.50% |
| 5 Years | 10.05 | 55.20 | 0.3609 | 15.36 | 946,121 | -9.66 | -96.12% |
Soligenix Description
| Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). |
